ClinicaliQ Trial Snapshot
- The PERSEVERE Study — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT06588634.
- What is being tested: The FlowTriever System (a mechanical thrombectomy device) versus standard care (anticoagulation ± thrombolysis) for treating high-risk pulmonary embolism, evaluating its safety and efficacy in removing clot burden and improving patient outcomes.
- Patient eligibility overview: High-risk pulmonary embolism patients (those with haemodynamic instability or right ventricular dysfunction) who are suitable for catheter-based intervention and meet specific inclusion/exclusion criteria regarding contraindications to standard therapies.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Randomized Controlled Trial of High-Risk Pulmonary Embolism Comparing FlowTriever System vs. Standard of Care
Eligibility Snapshot
- : 1. Age at enrollment ≥18 years 2. Objective evidence of a proximal filling defect in at least one main or lobar pulmonary artery 3. High-risk class of acute PE 4. RV dysfunction, as defined RV/LV ratio ≥1.0 5. Willing and able to provide informed consent, or if unable, through a Legal Authorized Representative, with permitting research without prior consent as a third option (for Europe and UK sites only), provided compliance with IRB/EC approvals and adherence to regulatory, ethical and national standards
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.